Walmar Clinical ApS: Financial statements 2024
CVR: 43237381
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Walmar Clinical ApS (CVR 43237381) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 1,946,435 and a net result of DKK 623,346 compared with DKK 725,164 the year before. That is an increase of 1.9% compared with the year before. Equity in the 2024 report amounted to DKK 666,157. The solvency ratio was 27.5%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 1,946,435
- Profit/Loss
- DKK 623,346
- Equity
- DKK 666,157
- Total Assets
- DKK 2,418,742
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 1.9 mio. | 623 t. | 666 t. | 1 |
| 2023 | - | 1.9 mio. | 725 t. | 775 t. | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Walmar Clinical ApS has published its annual report for 2023. Gross profit came to DKK 1,909,543, and the net result was DKK 725,164.
About Walmar Clinical ApS
Walmar Clinical ApS is a Danish company of the type Anpartsselskab based in Snekkersten, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Mikkel Walmar. The company is owned by 26c Holding ApS. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 1,847,721 and a net result of DKK 527,965 compared with DKK 623,346 the year before. Equity in the 2025 report amounted to DKK 932,122.